AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 39136801 — intervention group
Group type: EXPERIMENTAL
Intervention: TransCon PTH treatment
Number of subjects: 19
Study 39136801 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 19
Study 39137016 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak Sleep app (3 months of app use)
Number of subjects: 101
Study 39137016 — intervention group
Group type: COMPARATOR
Intervention: No-treatment control
Number of subjects: 101
Study 39137016 — intervention group
Group type: EXPERIMENTAL
Intervention: Between-group comparison
Number of subjects: 101
Study 39137044 — intervention group
Group type: EXPERIMENTAL
Intervention: Teplizumab
Number of subjects: 0
Study 39137044 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39137100 — intervention group
Group type: EXPERIMENTAL
Intervention: Vivinex XY1 IOL
Number of subjects: 100
Study 39137100 — intervention group
Group type: COMPARATOR
Intervention: Clareon CNA0T0 IOL
Number of subjects: 100
Study 39137167 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral resveratrol (40 mg twice a day for 1 week, then 20 mg twice a day for 6 months)
Number of subjects: 142
Study 39137167 — intervention group
Group type: COMPARATOR
Intervention: Matched oral placebo
Number of subjects: 142
Study 39137167 — intervention group
Group type: COMPARATOR
Intervention: Comparison of resveratrol vs placebo
Number of subjects: 142
Study 39137185 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kits offered to women overdue for cervical cancer screening (CC) during breast cancer screening.
Number of subjects: 27116
Study 39137185 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling kits offered to women overdue for colorectal cancer screening (CRC) during breast cancer screening.
Number of subjects: 27116
Study 39137185 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling offered to women overdue for CC screening.
Number of subjects: 27116
Study 39137185 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-sampling offered to women overdue for CRC screening.
Number of subjects: 27116
Study 39137205 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative motion (RM) splints
Number of subjects: 36
Study 39137205 — intervention group
Group type: COMPARATOR
Intervention: MCPJ blocking splints
Number of subjects: 36
Study 39137205 — intervention group
Group type: EXPERIMENTAL
Intervention: Both RM and MCPJ blocking splints
Number of subjects: 36
Study 39137411 — intervention group
Group type: EXPERIMENTAL
Intervention: RNT-targeting self-help mobile app (MyMoodCoach) used for up to 6 weeks (n=119)
Number of subjects: 236
Study 39137411 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (usual practice with no access to the app until after 6 weeks, n=117)
Number of subjects: 236
Study 39137411 — intervention group
Group type: EXPERIMENTAL
Intervention: RNT-targeting self-help mobile app (MyMoodCoach)
Number of subjects: 236
Study 39137411 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group
Number of subjects: 236
Study 39137414 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUSau (dyadic, psychoeducational intervention adapted for Australian context)
Number of subjects: 346
Study 39137414 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 346
Study 39137414 — intervention group
Group type: EXPERIMENTAL
Intervention: FOCUSau
Number of subjects: 346
Study 39137516 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva osmolality (SOsm)
Number of subjects: 38
Study 39137516 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum sodium (Na)
Number of subjects: 38
Study 39137617 — intervention group
Group type: EXPERIMENTAL
Intervention: In-beam Positron Emission Tomography (PET) monitoring during carbon therapy
Number of subjects: 9
Study 39137617 — intervention group
Group type: COMPARATOR
Intervention: Control CT
Number of subjects: 9
Study 39137624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester (25 g bis-octanoyl (R)-1,3-butanediol)
Number of subjects: 30
Study 39137624 — intervention group
Group type: COMPARATOR
Intervention: Placebo (taste, appearance, and calorie-matched containing canola oil)
Number of subjects: 30
Study 39137624 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketone ester
Number of subjects: 30
Study 39137624 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 39137977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent Calorie Restriction (iCR)
Number of subjects: 42
Study 39137977 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study 39138024 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal therapy (including thoracoamniotic shunts, antenatal steroids, and combination therapies)
Number of subjects: 435
Study 39138116 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal exome sequencing (pES)
Number of subjects: 56
Study 39138224 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent vaccine (QVR)
Number of subjects: 6558
Study 39138224 — intervention group
Group type: COMPARATOR
Intervention: Bivalent vaccine (BVR)
Number of subjects: 6558
Study 39138435 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer support intervention (10-week group course)
Number of subjects: 11
Study 39138436 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib 8 mg once daily (with option for up-titration to 9 mg) or 10 mg (7 days on/7 days off for 4 NSCLC patients)
Number of subjects: 35
Study 39138436 — intervention group
Group type: EXPERIMENTAL
Intervention: Erdafitinib
Number of subjects: 35
Study 39138496 — intervention group
Group type: EXPERIMENTAL
Intervention: TEAM-PA intervention
Number of subjects: 54
Study 39138516 — intervention group
Group type: EXPERIMENTAL
Intervention: Scaffolded games rehabilitation program
Number of subjects: 33
Study 39138516 — intervention group
Group type: COMPARATOR
Intervention: Algorithm control of game difficulty
Number of subjects: 33
Study 39138516 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions (scaffolded games and algorithm control)
Number of subjects: 33
Study 39138518 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodulin (human polyvalent immunoglobulin)
Number of subjects: 166
Study 39138518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 166
Study 39138518 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodulin
Number of subjects: 166
Study 39138518 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimodulin and Placebo
Number of subjects: 166
Study 39138537 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated Care Borderline (ICB)
Number of subjects: 100
Study 39138537 — intervention group
Group type: COMPARATOR
Intervention: Treatment as Usual (TAU)
Number of subjects: 100
Study 39138559 — intervention group
Group type: EXPERIMENTAL
Intervention: Land-based aerobic exercise program plus health education
Number of subjects: 48
Study 39138559 — intervention group
Group type: EXPERIMENTAL
Intervention: Water-based aerobic exercise program plus health education
Number of subjects: 48
Study 39138559 — intervention group
Group type: COMPARATOR
Intervention: Health education alone (active-control group)
Number of subjects: 48
Study 39138581 — intervention group
Group type: EXPERIMENTAL
Intervention: PReTEE (simplified three-view TEE protocol)
Number of subjects: 46
Study 39138581 — intervention group
Group type: COMPARATOR
Intervention: Conventional TEE
Number of subjects: 46
Study 39138591 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial Chemoembolization (TACE) using doxorubicin and lipiodol
Number of subjects: 104
Study 39138591 — intervention group
Group type: EXPERIMENTAL
Intervention: Genotyping of IL28B and ANGPT2 genes
Number of subjects: 104
Study 39138719 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PPF-block (5-mL injectates of 20 mg of ropivacaine plus 4 mg of dexamethasone)
Number of subjects: 195
Study 39138719 — intervention group
Group type: COMPARATOR
Intervention: Placebo PPF-injection (saline solution)
Number of subjects: 195
Study 39138719 — intervention group
Group type: EXPERIMENTAL
Intervention: Active PPF-block
Number of subjects: 195
Study 39138719 — intervention group
Group type: COMPARATOR
Intervention: Placebo PPF-injection
Number of subjects: 195
Study 39138762 — intervention group
Group type: EXPERIMENTAL
Intervention: Logotherapy counseling program (8 sessions)
Number of subjects: 58
Study 39138762 — intervention group
Group type: COMPARATOR
Intervention: Routine care (Control)
Number of subjects: 58
Study 39138826 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miR-122-5p, miR-151a-3p, miR-126-5p and miR-21-5p in the MASLD group
Number of subjects: 100
Study 39138826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of miR-151a-3p or miR-21-5p with leptin
Number of subjects: 100
Study 39138826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of miR-151a-3p with glucose
Number of subjects: 100
Study 39138826 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of miR-126-5p with leptin
Number of subjects: 100
Study 39138826 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miRNAs
Number of subjects: 100
Study 39138849 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of OCT-VFs (TCFA, r-MLA, h-PB, CP)
Number of subjects: 429
Study 39138849 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of two or more OCT-VFs
Number of subjects: 429
Study 39139188 — intervention group
Group type: EXPERIMENTAL
Intervention: SOC-RPM
Number of subjects: 27
Study 39139188 — intervention group
Group type: EXPERIMENTAL
Intervention: RPM-SOC
Number of subjects: 27
Study 39139188 — intervention group
Group type: EXPERIMENTAL
Intervention: RPM
Number of subjects: 27
Study 39139216 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic Diet (KD)
Number of subjects: 0
Study 39139216 — intervention group
Group type: COMPARATOR
Intervention: Ketone Ester
Number of subjects: 0
Study 39139216 — intervention group
Group type: COMPARATOR
Intervention: Control (water)
Number of subjects: 0
Study 39139218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (week 6 serum concentration >41.65 µg/ml)
Number of subjects: 436
Study 39139218 — intervention group
Group type: EXPERIMENTAL
Intervention: Vedolizumab (induction and post-induction serum concentrations)
Number of subjects: 436
Study 39139269 — intervention group
Group type: EXPERIMENTAL
Intervention: Early vitrectomy surgery in addition to antibiotic administration
Number of subjects: 40
Study 39139269 — intervention group
Group type: COMPARATOR
Intervention: Intravitreal antibiotic administration alone (standard of care)
Number of subjects: 40
Study 39139270 — intervention group
Group type: EXPERIMENTAL
Intervention: tezacaftor-ivacaftor (TEZ/IVA), 28 days treatment duration
Number of subjects: 13
Study 39139270 — intervention group
Group type: COMPARATOR
Intervention: placebo, 28 days treatment duration
Number of subjects: 13
Study 39139436 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine
Number of subjects: 2080
Study 39139436 — intervention group
Group type: COMPARATOR
Intervention: Contrast Medium
Number of subjects: 2080
Study 39139457 — intervention group
Group type: EXPERIMENTAL
Intervention: D-penicillamine therapy
Number of subjects: 76
Study 39140267 — intervention group
Group type: EXPERIMENTAL
Intervention: Unilateral focused ultrasound subthalamotomy (FUS-STN)
Number of subjects: 0
Study 39140267 — intervention group
Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 0
Study 39140289 — intervention group
Group type: EXPERIMENTAL
Intervention: Safusidenib treatment following biopsy and prior to surgical resection
Number of subjects: 0
Study 39140490 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA) 5-10 mg
Number of subjects: 1285
Study 39140490 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1285
Study 39140490 — intervention group
Group type: EXPERIMENTAL
Intervention: Obeticholic acid (OCA)
Number of subjects: 1285
Study 39140490 — intervention group
Group type: COMPARATOR
Intervention: Non-OCA patients (external control)
Number of subjects: 1285
Study 39140573 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-hospitalized patients
Number of subjects: 1198
Study 39140573 — intervention group
Group type: COMPARATOR
Intervention: Hospitalized patients
Number of subjects: 1198
Study 39140573 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall cohort
Number of subjects: 1198
Study 39140573 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 severity variables
Number of subjects: 1198
Study 39140690 — intervention group
Group type: EXPERIMENTAL
Intervention: Dry needling
Number of subjects: 30
Study 39140690 — intervention group
Group type: COMPARATOR
Intervention: Transcutaneous electrical nerve stimulation
Number of subjects: 30
Study 39140698 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based pelvic floor muscle training programme
Number of subjects: 48
Study 39140727 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine loading dose
Number of subjects: 56
Study 39140777 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine (DPH) 50 mg
Number of subjects: 20
Study 39140786 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgender women (with orchiectomy)
Number of subjects: 30
Study 39140786 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgender women (without orchiectomy)
Number of subjects: 30
Study 39140786 — intervention group
Group type: COMPARATOR
Intervention: Reference males
Number of subjects: 30
Study 39140786 — intervention group
Group type: COMPARATOR
Intervention: Reference females
Number of subjects: 30
Study 39140786 — intervention group
Group type: EXPERIMENTAL
Intervention: Transgender women (with and without orchiectomy)
Number of subjects: 30
Study 39140975 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal obesity (P-OB)
Number of subjects: 0
Study 39140975 — intervention group
Group type: COMPARATOR
Intervention: Control (normal paternal BMI)
Number of subjects: 0
Study 39141364 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 2 mg
Number of subjects: 654
Study 39141364 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib 4 mg
Number of subjects: 654
Study 39141364 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 654
Study 39141364 — intervention group
Group type: EXPERIMENTAL
Intervention: Baricitinib (both doses)
Number of subjects: 654
Study 39141378 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad plus Allopurinol (12 mg plus 300 mg)
Number of subjects: 159
Study 39141378 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol (300 mg)
Number of subjects: 159
Study 39141378 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 159
Study 39141378 — intervention group
Group type: EXPERIMENTAL
Intervention: Verinurad plus Allopurinol
Number of subjects: 159
Study 39141378 — intervention group
Group type: COMPARATOR
Intervention: Allopurinol
Number of subjects: 159
Study 39141379 — intervention group
Group type: EXPERIMENTAL
Intervention: Vergence/accommodative therapy
Number of subjects: 310
Study 39141382 — intervention group
Group type: EXPERIMENTAL
Intervention: EDTA-based chelation
Number of subjects: 959
Study 39141382 — intervention group
Group type: COMPARATOR
Intervention: Placebo infusion
Number of subjects: 959
Study 39141577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks (dose-escalation cohort)
Number of subjects: 106
Study 39141577 — intervention group
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa 1200 mg every 2 weeks (dose-expansion cohort)
Number of subjects: 106
Study 39141622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT) delivered over 4 weekly sessions comprising two face-to-face meetings and two telephone calls.
Number of subjects: 50
Study 39141622 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE) administered in booklet form.
Number of subjects: 50
Study 39141622 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep Restriction Therapy (SRT)
Number of subjects: 50
Study 39141622 — intervention group
Group type: COMPARATOR
Intervention: Sleep Hygiene Education (SHE)
Number of subjects: 50
Study 39141666 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-PTSD-5 screening tool
Number of subjects: 817
Study 39141666 — intervention group
Group type: EXPERIMENTAL
Intervention: PC-PTSD-5 item 4 (numbing)
Number of subjects: 817
Study 39141673 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide
Number of subjects: 0
Study 39141673 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 39141836 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable sutures
Number of subjects: 55
Study 39141836 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermabond
Number of subjects: 55
Study 39141836 — intervention group
Group type: EXPERIMENTAL
Intervention: Steri-Strips
Number of subjects: 55
Study 39141836 — intervention group
Group type: COMPARATOR
Intervention: Guardian satisfaction with length of stay
Number of subjects: 55
Study 39141836 — intervention group
Group type: COMPARATOR
Intervention: Guardian and physician satisfaction with the procedure
Number of subjects: 55
Study 39141836 — intervention group
Group type: COMPARATOR
Intervention: Guardian and physician-perceived pain
Number of subjects: 55
Study 39141853 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuroprosthesis
Number of subjects: 1
Study 39141854 — intervention group
Group type: EXPERIMENTAL
Intervention: Implanted brain-computer interface for communication
Number of subjects: 1
Study 39141899 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-guided ICBT with online discussion forum
Number of subjects: 107
Study 39141899 — intervention group
Group type: COMPARATOR
Intervention: Self-guided ICBT without online discussion forum
Number of subjects: 107
Study 39141899 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (with and without forum)
Number of subjects: 107
Study 39141987 — intervention group
Group type: EXPERIMENTAL
Intervention: soluble mRNA (100 μg/animal)
Number of subjects: 4
Study 39141987 — intervention group
Group type: EXPERIMENTAL
Intervention: C-terminal transmembrane mRNA (100 μg/animal)
Number of subjects: 4
Study 39141987 — intervention group
Group type: EXPERIMENTAL
Intervention: protein vaccine (400 μg/animal)
Number of subjects: 4
Study 39141987 — intervention group
Group type: COMPARATOR
Intervention: non-translatable RNA control (100 μg/animal)
Number of subjects: 4
Study 39142110 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigorous fluid management using monitoring of ECW ratio by bioelectrical impedance analysis (BIA) with bolus infusion of crystalloid fluid for dehydrated patients and diuretics for overhydrated patients.
Number of subjects: 167
Study 39142110 — intervention group
Group type: COMPARATOR
Intervention: Traditional fluid treatment without BIA monitoring.
Number of subjects: 167
Study 39142511 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDS containing 0 mg/ml liquid nicotine
Number of subjects: 520
Study 39142511 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDS containing 8 mg/ml liquid nicotine
Number of subjects: 520
Study 39142511 — intervention group
Group type: EXPERIMENTAL
Intervention: ENDS containing 36 mg/ml liquid nicotine
Number of subjects: 520
Study 39142511 — intervention group
Group type: COMPARATOR
Intervention: Cigarette-shaped plastic tube (control)
Number of subjects: 520
Study 39142675 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pathway intervention for pelvic fragility fractures
Number of subjects: 393
Study 39142675 — intervention group
Group type: COMPARATOR
Intervention: Current practice (control group)
Number of subjects: 393
Study 39142677 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate-reduced high-protein (CRHP) diet
Number of subjects: 100
Study 39142677 — intervention group
Group type: COMPARATOR
Intervention: Conventional diabetes (CD) diet
Number of subjects: 100
Study 39142680 — intervention group
Group type: EXPERIMENTAL
Intervention: Upfront dose-reduced chemotherapy (25% reduction)
Number of subjects: 587
Study 39142680 — intervention group
Group type: COMPARATOR
Intervention: Full-dose chemotherapy (fluoropyrimidine plus oxaliplatin)
Number of subjects: 587
Study 39142680 — intervention group
Group type: COMPARATOR
Intervention: Fluoropyrimidine monotherapy (full-dose)
Number of subjects: 587
Study 39142680 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-reduced chemotherapy (25% reduction)
Number of subjects: 587
Study 39142718 — intervention group
Group type: EXPERIMENTAL
Intervention: Davoceticept (ALPN-202) in combination with pembrolizumab (anti-PD-1)
Number of subjects: 2
Study 39142723 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors (SGLT2i)
Number of subjects: 82272
Study 39142723 — intervention group
Group type: COMPARATOR
Intervention: GLP-1 receptor agonists (GLP-1 RAs)
Number of subjects: 82272
Study 39142725 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) with predischarge DW-MRI assessment
Number of subjects: 495
Study 39142727 — intervention group
Group type: EXPERIMENTAL
Intervention: hs-cTnI-SPINCHIP POC test
Number of subjects: 1102
Study 39142727 — intervention group
Group type: COMPARATOR
Intervention: hs-cTnI-Architect
Number of subjects: 1102
Study 39142727 — intervention group
Group type: COMPARATOR
Intervention: high-sensitivity cardiac troponin T Elecsys
Number of subjects: 1102
Study 39142758 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioresorbable vascular scaffolds (BVS)
Number of subjects: 220
Study 39142758 — intervention group
Group type: COMPARATOR
Intervention: Drug-coated balloons (DCBs)
Number of subjects: 220
Study 39142758 — intervention group
Group type: COMPARATOR
Intervention: Drug-eluting stents (DES)
Number of subjects: 220
Study 39142926 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib (oral Janus kinase inhibitor)
Number of subjects: 35
Study 39143444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (CBI) with walking component; participants categorized as 'sedentary' (≤ 4999 daily steps) or 'not sedentary' (≥ 5000 daily steps)
Number of subjects: 89
Study 39143444 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Intervention (CBI)
Number of subjects: 89
Study 39143577 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-preferred music (group P)
Number of subjects: 217
Study 39143577 — intervention group
Group type: COMPARATOR
Intervention: Classical music (group C)
Number of subjects: 217
Study 39143577 — intervention group
Group type: COMPARATOR
Intervention: Control group (group N)
Number of subjects: 217
Study 39143588 — intervention group
Group type: EXPERIMENTAL
Intervention: JASP-1
Number of subjects: 0